NASDAQ:TMCI Treace Medical Concepts - TMCI Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Treace Medical Concepts, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $23.79 -0.68 (-2.78%) (As of 02/6/2023 12:00 AM ET) Add Compare Share Share Today's Range$23.69▼$24.3850-Day Range$22.12▼$26.2252-Week Range$12.48▼$26.50Volume98,483 shsAverage Volume311,212 shsMarket Capitalization$1.32 billionP/E RatioN/ADividend YieldN/APrice Target$28.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Treace Medical Concepts MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside17.7% Upside$28.00 Price TargetShort InterestBearish5.42% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.01Based on 8 Articles This WeekInsider TradingSelling Shares$13.09 M Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.65 out of 5 starsMedical Sector849th out of 1,027 stocksSurgical & Medical Instruments Industry92nd out of 105 stocks 2.5 Analyst's Opinion Consensus RatingTreace Medical Concepts has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $28.00, Treace Medical Concepts has a forecasted upside of 17.7% from its current price of $23.79.Amount of Analyst CoverageTreace Medical Concepts has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.42% of the float of Treace Medical Concepts has been sold short.Short Interest Ratio / Days to CoverTreace Medical Concepts has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Treace Medical Concepts has recently increased by 3.41%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldTreace Medical Concepts does not currently pay a dividend.Dividend GrowthTreace Medical Concepts does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TMCI. Previous Next 2.2 News and Social Media Coverage News SentimentTreace Medical Concepts has a news sentiment score of 0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Treace Medical Concepts this week, compared to 1 article on an average week.Search Interest2 people have searched for TMCI on MarketBeat in the last 30 days. MarketBeat FollowsOnly 2 people have added Treace Medical Concepts to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Treace Medical Concepts insiders have sold 2,141.70% more of their company's stock than they have bought. Specifically, they have bought $584,044.00 in company stock and sold $13,092,497.00 in company stock.Percentage Held by Insiders41.89% of the stock of Treace Medical Concepts is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions46.17% of the stock of Treace Medical Concepts is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Treace Medical Concepts are expected to remain at ($0.75) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Treace Medical Concepts is -29.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Treace Medical Concepts is -29.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTreace Medical Concepts has a P/B Ratio of 13.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Treace Medical Concepts (NASDAQ:TMCI) StockTreace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra Beach, Florida.Read More Receive TMCI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Treace Medical Concepts and its competitors with MarketBeat's FREE daily newsletter. Email Address TMCI Stock News HeadlinesFebruary 4, 2023 | americanbankingnews.comTreace Medical Concepts, Inc. (NASDAQ:TMCI) Director Richard W. Mott Sells 4,011 SharesFebruary 1, 2023 | americanbankingnews.comTreace Medical Concepts (NASDAQ:TMCI) Stock Price Down 5.6% Following Insider SellingFebruary 7, 2023 | Wall Street Watch Dogs (Ad)The #1 Energy Stock to BuyThe next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…February 1, 2023 | americanbankingnews.comJames T. Treace Sells 38,071 Shares of Treace Medical Concepts, Inc. (NASDAQ:TMCI) StockFebruary 1, 2023 | americanbankingnews.comInsider Selling: Treace Medical Concepts, Inc. (NASDAQ:TMCI) Director Sells $883,247.20 in StockJanuary 31, 2023 | finance.yahoo.comDespite currently being unprofitable, Treace Medical Concepts (NASDAQ:TMCI) has delivered a 25% return to shareholders over 1 yearJanuary 29, 2023 | americanbankingnews.comInsider Selling: Treace Medical Concepts, Inc. (NASDAQ:TMCI) Director Sells $674,723.63 in StockJanuary 9, 2023 | finance.yahoo.comTreace Medical Concepts Provides 2022 Preliminary Unaudited RevenueFebruary 7, 2023 | Wall Street Watch Dogs (Ad)The #1 Energy Stock to BuyThe next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…December 21, 2022 | finance.yahoo.comOwning 47% shares,institutional owners seem interested in Treace Medical Concepts, Inc. (NASDAQ:TMCI),December 20, 2022 | finance.yahoo.comTreace to Present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023December 19, 2022 | finance.yahoo.comTreace Medical Announces Expansion of Its Global IP Portfolio with the Grant of Two New U.S. PatentsDecember 9, 2022 | benzinga.comTreace Investor AlertDecember 5, 2022 | benzinga.comPomerantz Law Firm Investigates Claims On Behalf of Investors of Treace Medical Concepts, Inc. - TMCIDecember 5, 2022 | seekingalpha.comTreace Medical: Differentiated Offering In Lapiplasty Procedure, Rate BuyDecember 1, 2022 | finance.yahoo.comTreace Medical Concepts (TMCI) is on the Move, Here's Why the Trend Could be SustainableNovember 30, 2022 | barrons.comBronstein, Gewirtz & Grossman, LLC Announces Treace Medical Concepts, Inc. (TMCI) InvestigationNovember 28, 2022 | finance.yahoo.comTreace Receives FDA 510(k) Clearance for SpeedPlate™ Rapid Compression Implant TechnologyNovember 21, 2022 | businesswire.comINVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Treace Medical Concepts, Inc. and Encourages Investors with Losses to Contact the FirmNovember 21, 2022 | finance.yahoo.comTreace Announces First Patient Treated in MTA3D™ Adductoplasty® Clinical StudyNovember 14, 2022 | finance.yahoo.comHere's What Could Help Treace Medical Concepts (TMCI) Maintain Its Recent Price StrengthNovember 12, 2022 | seekingalpha.comTreace Medical Concepts, Inc. (TMCI) Q3 2022 Earnings Call TranscriptNovember 10, 2022 | finance.yahoo.comTreace Medical Concepts Third Quarter 2022 Earnings: Beats ExpectationsNovember 8, 2022 | finance.yahoo.comTreace Medical Concepts (TMCI) Reports Q3 Loss, Tops Revenue EstimatesNovember 8, 2022 | finance.yahoo.comTreace Medical Concepts Reports Third Quarter 2022 Financial ResultsOctober 29, 2022 | finance.yahoo.comBullish insiders at Treace Medical Concepts, Inc. (NASDAQ:TMCI) loaded up on US$1.3m of stock earlier this yearOctober 25, 2022 | finance.yahoo.comTreace Announces Participation in Upcoming Investor ConferencesSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive TMCI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Treace Medical Concepts and its competitors with MarketBeat's FREE daily newsletter. Email Address TMCI Company Calendar Last Earnings11/04/2021Today2/07/2023Next Earnings (Estimated)3/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TMCI CUSIPN/A CIK1630627 Webwww.treace.com Phone904-373-5940FaxN/AEmployees248Year FoundedN/APrice Target and Rating Average Stock Price Forecast$28.00 High Stock Price Forecast$29.00 Low Stock Price Forecast$27.00 Forecasted Upside/Downside+17.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,550,000.00 Net Margins-35.87% Pretax Margin-35.87% Return on Equity-51.67% Return on Assets-26.91% Debt Debt-to-Equity Ratio0.85 Current Ratio5.66 Quick Ratio4.92 Sales & Book Value Annual Sales$94.42 million Price / Sales13.98 Cash FlowN/A Price / Cash FlowN/A Book Value$1.75 per share Price / Book13.59Miscellaneous Outstanding Shares55,500,000Free Float32,252,000Market Cap$1.32 billion OptionableNot Optionable Beta-0.13 Key ExecutivesMr. John T. Treace (Age 51)CEO, Founder & Director Comp: $688.14kMr. Mark L. Hair CPA (Age 52)Chief Financial Officer Comp: $688.22kMr. Aaron Berutti (Age 44)Sr. VP of Sales Comp: $323.62kMr. Terry W. Lubben (Age 58)Sr. VP of Operations Mr. Scot Elder (Age 48)Chief Legal & Compliance Officer and Corp. Sec. Dr. Sean F. Scanlan Ph.D. (Age 41)Sr. VP of Marketing Mr. Daniel E. Owens (Age 51)Chief HR Officer Mr. Jaime A. Frias (Age 61)Chief Bus. Devel. Officer Ms. Shana ZinkSr. VP of Clinical Affairs, Medical Education & ReimbursementMs. Rachel OsbeckSr. VP of Quality Assurance & Regulatory AffairsMore ExecutivesKey CompetitorsParagon 28NYSE:FNANevroNYSE:NVROAtrionNASDAQ:ATRIAlphatecNASDAQ:ATECOrthoPediatricsNASDAQ:KIDSView All CompetitorsInsiders & InstitutionsLisanti Capital Growth LLCBought 62,405 shares on 2/6/2023Ownership: 0.112%Emerald Advisers LLCBought 67,481 shares on 2/3/2023Ownership: 2.141%Emerald Mutual Fund Advisers TrustBought 34,464 shares on 2/3/2023Ownership: 1.704%Essex Investment Management Co. LLCSold 2,994 shares on 2/3/2023Ownership: 0.252%Richard W MottSold 4,011 sharesTotal: $96,264.00 ($24.00/share)View All Insider TransactionsView All Institutional Transactions TMCI Stock - Frequently Asked Questions Should I buy or sell Treace Medical Concepts stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Treace Medical Concepts in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TMCI shares. View TMCI analyst ratings or view top-rated stocks. What is Treace Medical Concepts' stock price forecast for 2023? 3 Wall Street research analysts have issued 1-year target prices for Treace Medical Concepts' shares. Their TMCI share price forecasts range from $27.00 to $29.00. On average, they expect the company's stock price to reach $28.00 in the next twelve months. This suggests a possible upside of 17.7% from the stock's current price. View analysts price targets for TMCI or view top-rated stocks among Wall Street analysts. How have TMCI shares performed in 2023? Treace Medical Concepts' stock was trading at $22.99 at the start of the year. Since then, TMCI stock has increased by 3.5% and is now trading at $23.79. View the best growth stocks for 2023 here. When is Treace Medical Concepts' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023. View our TMCI earnings forecast. How were Treace Medical Concepts' earnings last quarter? Treace Medical Concepts, Inc. (NASDAQ:TMCI) issued its quarterly earnings results on Thursday, November, 4th. The company reported ($0.12) EPS for the quarter, meeting analysts' consensus estimates of ($0.12). The business had revenue of $21.62 million for the quarter, compared to the consensus estimate of $21.06 million. Treace Medical Concepts had a negative net margin of 35.87% and a negative trailing twelve-month return on equity of 51.67%. What guidance has Treace Medical Concepts issued on next quarter's earnings? Treace Medical Concepts updated its FY 2022 earnings guidance on Friday, January, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $141.20 million-$141.70 million, compared to the consensus revenue estimate of $137.01 million. When did Treace Medical Concepts IPO? (TMCI) raised $150 million in an initial public offering on Friday, April 23rd 2021. The company issued 9,400,000 shares at $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and SVB Leerink and Stifel were co-managers. What is Treace Medical Concepts' stock symbol? Treace Medical Concepts trades on the NASDAQ under the ticker symbol "TMCI." Who are Treace Medical Concepts' major shareholders? Treace Medical Concepts' stock is owned by a variety of institutional and retail investors. Top institutional investors include Emerald Advisers LLC (2.14%), Emerald Mutual Fund Advisers Trust (1.70%), Allspring Global Investments Holdings LLC (0.86%), Calamos Advisors LLC (0.29%), Essex Investment Management Co. LLC (0.25%) and Lisanti Capital Growth LLC (0.11%). Insiders that own company stock include Aaron Berutti, Daniel E Owens, F Barry Bays, Jaime A Frias, James T Treace, John R Treace, John T Treace, Mark Hair, Richard W Mott, Scot Michael Elder, Sean F Scanlan, Terry W Lubben and Thomas E Timbie. View institutional ownership trends. How do I buy shares of Treace Medical Concepts? Shares of TMCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Treace Medical Concepts' stock price today? One share of TMCI stock can currently be purchased for approximately $23.79. How much money does Treace Medical Concepts make? Treace Medical Concepts (NASDAQ:TMCI) has a market capitalization of $1.32 billion and generates $94.42 million in revenue each year. The company earns $-20,550,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. How many employees does Treace Medical Concepts have? The company employs 248 workers across the globe. How can I contact Treace Medical Concepts? Treace Medical Concepts' mailing address is 203 FORT WADE RD. SUITE 150, PONTE VEDRA FL, 32081. The official website for the company is www.treace.com. The company can be reached via phone at 904-373-5940 or via email at ir@treace.net. This page (NASDAQ:TMCI) was last updated on 2/7/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.